BioSpace News Archive

A hot, humid summer will slow coronavirus transmission but, on its own isn’t likely to end the COVID-19 pandemic, according to a new study.

Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.

The mounting cases of people suffering from respiratory disorders is the foremost factor driving the global respiratory diagnostics market.

According to the report, the global ultrasound gels market was valued at ~US$ 310 Mn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.

Smart inhalers are increasingly becoming the preferred course of managing and treating respiratory diseases.

Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD)

Castlight Health, Inc. (NYSE: CSLT) today announced the launch of Working WellTM, an end-to-end solution that helps employers of any size manage safe workforce re-entry in the rapidly shifting landscape of the COVID-19 pandemic.

AVRA Medical Robotics, Inc. (“AVRA” or “the Company”) (OTC: AVMR) today issued the following update: Despite the difficulties presented by the COVID-19 Pandemic, the Company continues to make progress on developing its proprietary Medical Robotic System. As AVRA CEO Barry Cohen explains, “The latest test results of AVRA’s Imaging and Detection System software designed to Detect, Identify, Diagnose, and Deliver an autonomous robotic surgical pr

Livanta LLC was honored with a Spotlight Award from the Centers for Medicare & Medicaid Services (CMS) for The Livanta Compass e-newsletter. The weekly publication was recognized as an effective communication vehicle for reaching rural communities to build awareness of Livanta’s activities as a Medicare Beneficiary and Family Centered Care Quality Improvement Organization (BFCC-QIO). The inaugural Spotlight Awards were presented

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates: Normal commercial operations will recommence from 1 June 2020 Confirmed that a prototype polygenic risk score can successfully discriminate between COVID-19 patients who required hospitalization from those who did not require hospitalization Continued discussions with third parties around use of existing CLIA and NATA accr